comparemela.com

Latest Breaking News On - சர்வதேச டயல் செய்யுங்கள் இல் - Page 6 : comparemela.com

Ampco-Pittsburgh (NYSE: AP) Fourth Quarter and Fiscal Year 2020 Results Conference Call

Press release content from Business Wire. The AP news staff was not involved in its creation. Ampco-Pittsburgh (NYSE: AP) Fourth Quarter and Fiscal Year 2020 Results Conference Call March 1, 2021 GMT CARNEGIE, Pa. (BUSINESS WIRE) Mar 1, 2021 Ampco-Pittsburgh Corporation (NYSE: AP) will hold a conference call on Thursday, March 18, 2021, at 10:30 a.m. Eastern Time (ET) to discuss its financial results for the fourth quarter and fiscal year ended December 31, 2020. The Corporation expects to issue its earnings press release on Wednesday, March 17, 2021. If you would like to participate in the conference call, please register using the link below or by dialing 1-844-308-3408 at least five minutes before the 10:30 a.m. ET start time.

CORRECTING and REPLACING Danaos Corporation Announces Date for the Release of Fourth Quarter 2020 Results, Conference Call and Webcast

DANAOS CORPORATION ANNOUNCES DATE FOR THE RELEASE OF FOURTH QUARTER 2020 RESULTS, CONFERENCE CALL AND WEBCAST Danaos Corporation (NYSE: DAC), one of the world's largest independent owners of containerships

Ergomed acquires MedSource, a US-based specialist oncology and rare disease CRO

·           Guildford, UK – 14 December 2020: Ergomed plc (LSE: ERGO) ( Ergomed or the Company ), a company focused on providing specialised services to the pharmaceutical industry, today announces the acquisition of MS Clinical Services, LLC (“MedSource”), a specialised clinical research organisation (CRO) based in Houston, Texas, USA. Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: “We are delighted to have delivered on our strategic goals in 2020 with the expansion of our US footprint in both the CRO and PV businesses. The addition of MedSource and its complementary expertise in oncology and rare disease will further establish Ergomed as a specialised services provider in the strategically important US market, building on the successful acquisition and integration of Ashfield Pharmacovigilance (now PrimeVigilance USA) earlier this year. We look forward to developing the potential of this new business to offer truly global clinical research s

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.